{"source":"kalshi","id":"KXBEPIROVIRSEN-27","ticker":"KXBEPIROVIRSEN-27","slug":"KXBEPIROVIRSEN-27","title":"FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)","description":null,"image":null,"icon":null,"active":true,"closed":false,"start_date":"2026-06-17T21:00:00Z","end_date":"2027-01-08T15:00:00Z","closed_time":null,"volume":254.19,"volume_24hr":2.0,"volume_24h_change":null,"normalized_vol_24hr":0.43521735072135925,"normalized_volume":8.491447448730469,"liquidity":null,"open_interest":164.99,"categories":["Finance"],"tags":[],"synthetic":false,"is_group":false,"group_key":null,"parent_event_id":null,"probability":null,"spread":null,"top_outcome":"a full approval or an accelerated approval","top_outcome_probability":0.76,"top_outcome_prob_24h_change":0.0,"top_outcome_volume_24h_change":0.0,"updated_at":"2026-08-16T21:41:37.142087Z","fetched_at":"2026-08-16T21:41:37.142087Z","added_at":"2026-06-17T21:13:38.461385Z","url":"https://kalshi.com/markets/kxbepirovirsen/fda-decision-bepirovirsen-by-glaxosmithkline-in-2026/kxbepirovirsen-27","chart_24h":null,"markets":[{"source":"kalshi","id":"KXBEPIROVIRSEN-27-Y","event_id":"KXBEPIROVIRSEN-27","slug":"KXBEPIROVIRSEN-27-Y","question":"What will the FDA's decision be on Bepirovirsen by GlaxoSmithKline in 2026?","group_item_title":"a full approval or an accelerated approval","description":"If the FDA's decision on Bepirovirsen by GlaxoSmithKline in 2026 is a full approval or an accelerated approval, the market resolves to Yes.\n\n---\n\nThis market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. \n\nBepirovirsen is an experimental antiviral medicine developed by GlaxoSmithKline that is designed to clear the hepatitis B virus from the body rather than just keeping it asleep. It belongs to a modern class of gene-silencing therapies that hunt down and destroy the virus's replication instructions. This is similar to intercepting and shredding a virus’s blueprints before its cell-invading factory has a chance to read them and build new viral copies.","image":null,"icon":null,"outcomes":["Yes","No"],"outcome_prices":[0.76,0.24],"probability":0.76,"spread":0.07000000000000006,"active":true,"closed":false,"start_date":"2026-06-17T21:00:00Z","end_date":"2027-01-08T15:00:00Z","closed_time":"2027-01-01T04:59:00Z","volume":254.19,"volume_24hr":2.0,"prob_24h_change":0.0,"volume_24h_change":0.0,"normalized_vol_24hr":0.4712848365306854,"normalized_volume":9.561229705810547,"liquidity":null,"categories":["Finance"],"countries":["United States"],"updated_at":"2026-08-17T11:36:47.574659Z","fetched_at":"2026-08-17T11:36:47.574659Z","added_at":"2026-06-17T21:13:38.591203Z","url":"https://kalshi.com/markets/kxbepirovirsen/fda-decision-bepirovirsen-by-glaxosmithkline-in-2026/kxbepirovirsen-27","event_title":"FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)","chart_24h":[0.76,0.76,0.76,0.76,0.76,0.76]}],"_meta":{"attribution":"pdata.world — aggregated prediction-market data across 8 platforms","canonical_url":"https://pdata.world/events/kalshi/KXBEPIROVIRSEN-27","as_of":"2026-08-17T14:07:36.875050Z","docs":"https://api.pdata.world/docs","cite_as":"According to pdata.world (tracking Kalshi): \"FDA decision: Bepirovirsen by GlaxoSmithKline (in 2026)\" — top market at 76% probability across 1 outcome","source_url":null}}